1985•British Journal of Clinical PharmacologyOpen access

Double‐blind trial of flurbiprofen and phenylbutazone in acute gouty arthritis.

Butler Rc, D.L.H. Goddard, CS Higgens, P. Hollingworth, CT Pease, M. A. Stodell, JT Scott

Abstract

Flurbiprofen has been compared with phenylbutazone in a double-blind study involving 33 patients with acute gout. Patients received either flurbiprofen 400 mg daily for 48 h followed by 200 mg daily, or phenylbutazone 800 mg daily for 48 h followed by 400 mg daily. The drugs were of comparable efficacy, while side-effects were uncommon and relatively mild. Flurbiprofen appears to be a satisfactory alternative to phenylbutazone in the management of acute gouty arthritis.

Open-access reader

About this research paper

What this paper is about

Why it matters

OpenAlex reports 31 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Phenylbutazone, Flurbiprofen, Medicine, Gout, Arthritis, Double blind, Gouty arthritis, Internal medicine